Crizanlizumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized |
| Target | selectin P |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| ChemSpider |
|
Crizanlizumab is a monoclonal antibody developed by Novartis targeted towards P-selectin. It was announced by the company as an effective drug to prevent vaso-occlusive crisis in patients with Sickle cell anemia. The result of the Phase II SUSTAIN clinical trial was published in December 2016.[1]
Pathophysiology
P-selectin molecules are present on the surface of vascular endothelial cells and have been linked to Sickle cell vaso-occlusive crises.[2]
References
- ^ "Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease". New England Journal Medicine. Retrieved 5 December 2016.
- ^ "Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies" (122(24)). 2013: 3892–3898.
{{cite journal}}:|access-date=requires|url=(help); Cite journal requires|journal=(help)